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Fibronectin augments monocyte adhesion to low-density lipoprotein- within the mesangium may set up a chronic inflammatory
stimulated mesangial cells. reaction that leads to altered mesangial cell function andBackground. Glomerular monocyte infiltration is an early feature
promotes matrix deposition. Previous in vitro studiesof lipid-mediated renal injury in animal models. Interactions between
mesangial and infiltrating mononuclear cells may contribute to the have demonstrated that the addition of low-density lipo-
development of glomerular scarring. protein (LDL) to mesangial cells in culture results inMethods. Adherence of U-937 monocytes to low-density lipoprotein
(LDL)- or tumor necrosis factor a (TNFa)-prestimulated human mes- increased production of matrix components including
angial cells was assessed by colorimetry of nuclear staining with crystal fibronectin, a high molecular weight glycoprotein con-
violet. Blocking antibodies were added to examine the mechanisms of
taining functionally and structurally distinct domains,binding. Adhesion molecule expression and fibronectin synthesis were
measured by ELISA. some of which interact with cell surface receptors [4–6].
Results. Preincubation of mesangial cells for 24 hours with LDL Mesangial cells also oxidize LDL and thereby modify its
(100 mg/ml) or mildly oxidized (minimally modified) LDL (MM-LDL)
effects on cell function, rendering the lipoprotein cyto-increased monocyte adhesion by 207% and 240%, respectively, com-
pared with control nonstimulated cells (100%). TNFa (100 U/ml) toxic at high physiological concentrations [7].
enhanced binding by 335% and up-regulated intercellular adhesion mol- A small proportion of cells in the normal glomerularecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) ex-
mesangium are bone marrow-derived monocytes. Al-pression by 505% and 179%, respectively, as compared with MM-LDL
(120% and 116%) and LDL, which had no effect. Blocking antibodies though their precise function is unclear, their numbers
to these adhesion molecules inhibited monocyte binding to TNFa- and,
increase in most forms of glomerulonephritis, as well asto a lesser extent, MM-LDL-primed mesangial cells, but had no effect
after LDL pretreatment. In contrast to TNFa, MM-LDL and LDL in the early stages of glomerular scarring in experimental
increased mesangial cell-associated fibronectin, whereas antibodies to animal models [8–11]. The recruitment of these addi-
fibronectin inhibited monocyte binding to lipoprotein-stimulated but
tional cells may be driven by the accumulation of chemo-not TNFa-stimulated cells.
Conclusions. Although enhanced monocyte adhesion to TNFa- and, tactic substances within the mesangium and is likely to
to a lesser extent, MM-LDL-stimulated mesangial cells is mediated by involve the co-ordinated expression of leukocyte adhe-
changes in ICAM-1 and VCAM-1 expression, both LDL and MM-LDL
sion molecules on the activated glomerular endothelium.promote similar cellular interactions as a result of increased fibronectin
production. Once within the mesangium, monocytes are likely to inter-
act with adjacent nonimmune cells and may alter their
biological function, thereby contributing to the develop-
In small mammals fed high-cholesterol diets, deposi- ment of scarring. Such interactions may involve the local
tion of lipoproteins and accumulation of monocytes production of cytokines such as tumor necrosis factor a
within the mesangium precede the development of glo- (TNFa) and other mediators. In addition, monocytes may
merulosclerosis [1]. Experimental interventions designed adhere directly to mesangial cells, a process that is likely
to lower plasma lipid levels or to inactivate mononuclear to involve mesangial cell surface adhesion molecules
cells prevent scarring, suggesting that these early events such as intercellular adhesion molecule-1 (ICAM-1) and
may contribute to glomerular injury [2, 3]. It has there- vascular cell adhesion molecule-1 (VCAM-1), which
fore been proposed that the accumulation of lipoproteins bind to the monocyte integrins leukocyte functional associ-
ated molecule-1 (LFA-1) and very late antigen-4 (VLA-4),
respectively [11–13]. Both VLA-4 and the closely relatedKey words: glomerular scarring, low density lipoprotein, adhesion
molecule, glomerulosclerosis, plasma lipid level. integrin VLA-5 also interact to fibronectin, VLA-4 with
the alternatively spliced domain (CS-1) and VLA-5 with
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expression of cell adhesion molecules or through increas- protein was mildly oxidized (minimally modified) by
storage at 48C for approximately three to four months.ing synthesis and secretion of fibronectin.
The aim of these studies was therefore to examine Oxidation was confirmed by assessment of electropho-
retic mobility on agarose gel and by measurement ofthe effect of unmodified and mildly oxidized LDL on
monocyte adhesion to mesangial cells. The macrophage- thiobarbituric reactive substances content [7]. Modified
lipoprotein had an increased electrophoretic mobilityderived cytokine TNFa, which is known to enhance mes-
angial adhesion molecule expression and mononuclear when compared with freshly isolated LDL. The thiobar-
bituric reactive substances content of LDL and minimallycell binding, was used as a positive control [14]. Having
established that lipoprotein stimulation enhanced mono- modified-LDL (MM-LDL) was less than 3 and between
4 and 8 nm malondialdehyde/mg lipoprotein concentra-cyte binding, the mechanisms of this interaction were
explored. Because LDL had no effect on mesangial cell tion, respectively. Lipoprotein preparations were shown
to be free of endotoxin contamination using an E-Toxateadhesion molecule expression, the possible role of fi-
bronectin as a mediator of this interaction was investi- kit (Sigma Chemical Co., Poole, UK). Prior to use, lipo-
protein samples were extensively dialyzed against 0.15 mgated. The results indicate that enhanced synthesis of
matrix may play a key role in promoting monocyte accu- NaCl, 0.3 mm EDTA (pH 7.4) buffer prepared in pyrogen-
free sterile water and were sterilized by passage throughmulation in the glomerular mesangium.
0.22 mm filter. The protein content of the samples was
determined using the method of Lowry [17].
METHODS
Mesangial cell culture The U-937 monocyte adhesion assay
The binding of U-937 cells to mesangial cells was de-Human mesangial cells were established in culture
as previously described [7]. Briefly, cortical tissue was termined using a colorimetric method as described by
Mene` et al [14]. Briefly, cells plated at a density of 20,000obtained from macroscopically normal areas of nephrec-
tomy specimens. Glomeruli were separated by differential cells/well in 24-well tissue culture plates were grown for
96 hours, growth arrested for 48 hours in serum-freesieving, collagenase digested and plated in RPMI medium
supplemented with 20% fetal calf serum, l-glutamine (300 medium, and then stimulated with either LDL (25 to
100 mg/ml), MM-LDL (25 to 100 mg/ml), or TNFa (100mg/ml), insulin (5 mg/ml), transferrin (5 mg/ml), selenium
(5 ng/ml), penicillin (100 IU/ml), and streptomycin (100 U/ml) for 24 hours (or for 4, 8, 24, and 48 hr during
the time-course studies). After rinsing three times withmg/ml). Stellate-shaped mesangial cells, which outgrow
other cell types, were subcultured into multiwell plates sterile phosphate-buffered saline (PBS), a suspension of
U-937 monocytes (2 3 106 cells/well) in RPMI mediumfor the purposes of these experiments and were used
between passages 3 and 10. The characterization of these was added and the coculture incubated for one hour
at 378C. The nonadhered monocytes were removed bycells has been described in detail elsewhere [15, 16]. All
experiments were performed using growth-arrested cells washing three times with sterile PBS, and those adherent
to the mesangial cells were fixed for 20 minutes withthat were stimulated in serum-free medium.
Human myelomonocytic leukemia cells of the U-937 1.0% glutaraldehyde. After washing and air drying, cells
were stained with a crystal violet solution (0.1% wt/vol)cell line (European Collection of Cell Culture, Salisbury,
UK) were grown in supplemented RPMI 1640 medium for 15 minutes, were rinsed five times with sterile water,
and were solubilized in triton X-100 (1.0%) overnight.as described above. Cultures were expanded by seeding
approximately 2 3 106 cells into 15 ml 20% fetal calf The absorbance readings were recorded at 595 nm using
a spectrophotometer (Titertex Multiscan; Labsystemsserum/RPMI medium in T75 culture flasks (Falcon Sci-
entific Supplies, London, UK) and were fed every four Ltd., Basingstoke, UK). The results were subtracted
from background readings resulting from staining ofdays. Before adhesion assays, cells were centrifuged at
1,000 g for five minutes. The monocyte pellet was rinsed mesangial cells alone. The corrected readings were then
taken to be proportional to the number of monocytestwice in RPMI medium and was resuspended to a known
cell concentration in the experimental incubation me- bound and were expressed as the percentage adherence
of control (100% representing unstimulated mesangialdium.
cells grown in RPMI medium alone).
Isolation and modification of LDL The cellular mechanisms that mediate monocyte adhe-
sion to human mesangial cells were studied using a vari-Low-density lipoprotein (density range 1.019 to 1.063
g/ml) was isolated from plasma obtained from healthy ety of blocking antibodies, including anti-human ICAM-1
(CD54; 10 mg/ml; R&D Systems Europe Ltd., Abingdon,volunteers by sequential ultracentrifugation in the pres-
ence of antioxidants and in endotoxin-free reagents as Oxon, UK), anti-human VCAM-1 (CD106; 4 mg/ml; R&D
Systems), anti-human LFA-1 (20 mg/ml; R&D Systems),described previously [7]. Samples were aliquoted, stored
at 48C, and used within five weeks of preparation. Lipo- anti-human fibronectin (25 mg/ml; Sigma), anti-VLA-4
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(10 mg/ml; AMS Biotechnology, Witney, Oxon, UK), medium samples were incubated overnight in wells that
had been precoated with a rabbit polyclonal anti-humanand anti-VLA-5 (5 mg/ml; AMS Biotechnology). In each
case, a variety of antibody dilutions were used based on fibronectin antibody (1:1000; Sigma). This was followed
by the addition of a mouse monoclonal anti-human fi-published data such that a saturating antibody concentra-
tion could be chosen. Following lipoprotein or cytokine bronectin (1:500; Sigma) and a horseradish peroxidase-
conjugated anti-mouse antibody (1:1000; Dako) for twostimulation, cells were washed twice with RPMI medium
and were incubated for two to three hours with anti- hours each. Plates were then developed using a pheny-
lenediamine substrate. After the color had developedICAM-1, anti-VCAM-1, or anti-fibronectin antibodies
prepared in RPMI before adding the U-937 monocytes sufficiently, the reaction was stopped by adding 1 m sulfu-
ric acid, and the absorbance was recorded at 492 nm.to the cells as described above. Alternatively, monocytes
were preincubated with anti-VLA-4, anti-VLA-5, or anti- The cell extract was measured for protein using the Bio-
Rad DC protein assay kit II (Bio-Rad Laboratories Ltd.,LFA-1 antibodies for 30 minutes at room temperature
prior to conducting the adhesion assay. Hemel Hempstead, Hertfordshire, UK). All fibronectin
concentrations were then corrected for cell protein, and
Expression of adhesion molecules measured by the results were expressed as ng/mg cell protein.
cell ELISA
Statistical analysisThe expression of ICAM-1 and VCAM-1 was mea-
sured using a cell ELISA. Mesangial cells plated at a Statistical analysis was performed using a Mann–Whit-
ney unpaired nonparametric two-tailed test or wheredensity of 10,000 cells/well in 96-well plates were grown
for 96 hours in supplemented RPMI, growth arrested in stated by paired Student’s t-test or by analysis of variance
(ANOVA). Results are expressed as mean 6 sem. P lessserum free medium for 48 hours, and stimulated with
either LDL (25 to 100 mg/ml), MM-LDL (25 to 100 mg/ml), than 0.05 was considered significant.
or TNFa (100 U/ml) for 24 hours (or for 4, 8, 24, and
48 hr during the time-course study). After stimulation,
RESULTS
the cells were washed three times with PBS and were
Adherence of U-937 monocytes to mesangial cellsfixed with 0.1% glutaraldehyde for one hour at 48C.
After removing the fixative and washing three times with U-937 monocytes adhered strongly even to unstimu-
lated human mesangial cells growth arrested in serum-PBS, cells were air dried overnight and blocked for non-
specific binding with 10% powdered milk prepared in free medium (Fig. 1). Binding occurred predominantly
to the cell surface with minimal adhesion to the uncoatedPBS. The plates were then incubated with 100 ml of either
anti-human ICAM-1 (1:400) or anti-human VCAM-1 plastic plate. Prior exposure of mesangial cells to lipopro-
teins or TNFa led to an increase in monocyte binding(1:1000) antibodies in 10% powdered milk. These anti-
body dilutions had been optimized by prior titration stud- as shown in Figure 2. Compared with control (100%;
cells exposed to RPMI medium alone), preincubationies. The primary antibody was omitted in control wells.
After incubating for one hour at room temperature, cells with 100 mg/ml LDL led to an increase in mean (sem)
monocyte binding from 130.1% (4.5%, P , 0.005) atwere washed three times with 10% powdered milk, and
100 ml of peroxidase-conjugated rabbit anti-mouse im- four hours to 219.9% (3.6%, P , 0.005) at eight hours,
and 298.0% (33.9%, P , 0.005) at 24 hours. Longermunoglobulin (1:600; Dako Ltd., Ely, Cambridge, UK)
was added to each well. The plates were incubated for preincubation periods led to a fall in monocyte binding.
Monocyte adhesion to mesangial cells prestimulated fora further one hour at room temperature. Following two
additional washes with 10% powdered milk and three various periods with MM-LDL and TNFa showed simi-
lar profiles of time dependency, peaking at 24 hours.with PBS, the ELISA was developed using a phenylene-
diamine substrate prepared in citrate buffer containing This was therefore set as the priming period used for
further experiments. These effects could not be ac-0.006% hydrogen peroxide for approximately one hour
at room temperature. The absorbance reading was re- counted for by altered cell viability or by changes in
mesangial cell numbers. However, 3H-thymidine incor-corded at 450 nm using a spectrophotometer.
poration was increased by 24-hour stimulation with LDL,
Fibronectin assay MM-LDL, and TNFa stimulation, suggesting a prolifera-
tive response. In contrast, proliferation was inhibitedThe synthesis of fibronectin by cultured mesangial cells
treated with lipoproteins and TNFa was measured by when compared with control after 48-hour exposure to
lipoproteins (data not shown).ELISA as described by Burton et al [18]. Briefly, growth-
arrested cells grown in 24-well plates were exposed to The effects of LDL and MM-LDL on monocyte bind-
ing to mesangial cells were concentration dependent upLDL (50 and 100 mg/ml), MM-LDL (50 and 100 mg/ml),
or TNFa (100 U/ml) for 24 hours. The standards and to 100 mg/ml as shown in Figure 3. At 100 mg/ml, mono-
cyte adhesion to LDL- and MM-LDL–primed mesangialappropriately diluted cell layer extract and conditioned
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Fig. 1. Adhesion of U-937 monocytes to hu-
man mesangial cells. U-937 monocytes were
coincubated with growth-arrested (A) or low
density lipoprotein (LDL)-stimulated mesan-
gial cells (B) in serum free medium for one
hour. After washing, adhered monocytes were
fixed and stained with crystal violet. Note the
lack of adhesion to the base of the culture
dish between mesangial cells (original magni-
fication 3100).
cells was increased to 206.8% (31.9%, P , 0.005) and small but statistically significant increase in the expres-
sion of this adhesion molecule, whereas LDL had no240.2% (48.4%, P , 0.005) of control, respectively, an
effect (Fig. 4). Thus, when compared with control cellseffect comparable to that obtained by prior exposure to
grown in RPMI 100%, cells exposed to 50 mg/ml and100 U/ml TNFa [335.2% (45.0%), P , 0.005 vs. control].
100 mg/ml MM-LDL for 24 hours showed a 115.7 (2.2%,There was no statistically significant difference between
P , 0.05) and 119.9% (5.2%, P , 0.01) increase inthe effects of the two lipoproteins at these concentrations.
ICAM-1 expression, respectively. Further increases in
Expression of adhesion molecules lipoprotein concentrations did not enhance these effects.
In contrast, 100 U/ml TNFa increased ICAM-1 expres-To understand the cellular mechanisms involved
in these interactions, the expression of ICAM-1 and sion by 412.2% (63.9%, P , 0.001) under the same exper-
imental conditions (data not shown).VCAM-1 on mesangial cells was assessed. Cells grown
in serum-free conditions constitutively expressed low To confirm that peak expression of this adhesion mole-
cule had not been missed using the 24-hour time point,levels of ICAM-1. Prestimulation with MM-LDL at con-
centrations of between 50 and 100 mg/ml resulted in a a time-course study was undertaken. This confirmed that
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Fig. 4. ICAM-1 expression by lipoprotein-stimulated cells. Growth ar-Fig. 2. Time-dependency of adhesion of U-937 monocytes to prestimu-
rested mesangial cells were exposed to various concentrations of LDLlated human mesangial cells. Monocytes were incubated for one hour
and MM-LDL for 24 hours. Expression of ICAM-1 was assessed bywith mesangial cells that had been prestimulated for various time peri-
ELISA. The absorbance readings obtained (mean 6 sem) are expressedods with low density lipoprotein (LDL; 100 mg/ml), minimally modified
as percentage of control (unstimulated) cells (100%). Results are repre-(MM)-LDL (100 mg/ml) and tumor necrosis factor a (TNFa; 100 U/ml).
sentative of 5 experiments, each conducted in quintuplicate (*P , 0.01Adhered monocytes were fixed, stained, solubilized and quantitated by
vs. control). Symbols are: ( ) LDL; (j) MM-LDL.recording absorbance readings at 595 nm. The mean (sem) of triplicate
absorbance readings, corrected for background staining of mesangial
cells is expressed as percentage of control (unstimulated, growth ar-
rested cells in RPMI). The results are representative of those obtained in
2 similar experiments. P vs. control: *P , 0.005, **P , 0.001 (ANOVA).
Symbols are: (h) LDL; ( ) MM-LDL; (j) TNFa.
Fig. 5. Time course of ICAM-1 expression. Growth arrested mesangial
cells were exposed to LDL (100 mg/ml; ), MM-LDL (100 mg/ml;
) or TNFa (100 U/ml; ) for 4, 8, 24 and 48 hours. Results are
expressed as mean (sem) percentage over control (unstimulated) cells
and are representative of 3 similar experiments, each conducted in
quintuplicate. P vs. control: *P , 0.001, **P , 0.0001 (ANOVA).
Fig. 3. Adhesion of U-937 monocytes to human mesangial cells pre-
stimulated with varying concentrations of LDL, MM-LDL and TNFa
for 24 hours. (See Fig. 2.) Monocytes were incubated for 1 hour with
ineffective, regardless of the exposure period (Fig. 5).mesangial cells that had been prestimulated with various concentrations
of LDL, MM-LDL and TNFa. The results shown are mean (sem) of These results also highlight the magnitude of the differ-
6 experiments, each conducted in triplicate. P vs. control: *P , 0.05, ence between cytokine- and MM-LDL–induced effects
**P , 0.005.
on adhesion molecule expression. TNFa led to a time-
dependent increase in ICAM-1 expression, which at 48
hours reached 653.2% (21.81%, P , 0.0001) versus con-
trol (100%, ANOVA).the maximal effect of MM-LDL [in this experiment
130.2% (5.7%), P , 0.001 vs. control] was observed fol- Like ICAM-1, VCAM-1 was constitutively expressed
by mesangial cells. Although the magnitude of the effectlowing 24-hour preincubation. This was the same time
taken to induce peak adhesion of monocytes. LDL was was less marked than with ICAM-1, TNFa prestimula-
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bodies to LFA-1, a b2 integrin that binds to ICAM-1,
inhibited monocyte binding to TNFa-primed cells by
24.8% (2.7%, P , 0.0001) but had little effect on cells
exposed to either LDL or MM-LDL. In contrast, a mouse
anti-human fibronectin antibody had a maximal inhibi-
tory effect on binding of monocytes to LDL- [32.2%
(4.9%), P , 0.001] and MM-LDL–primed mesangial
cells [28.1% (3.4%), P , 0.001] but only blocked binding
following TNFa-priming by 12.1% (3.6%, P , 0.05).
Antibodies directed against VLA-5, the monocyte inte-
grin that binds to the RGD sequence of the fibronectin
molecule showed a similar pattern of inhibition in LDL
[42.9% (4.6%), P , 0.0001] and MM-LDL [37.9% (2.7%),
P , 0.0001] prestimulated cells, respectively, but did not
effect binding to cells primed with TNFa. Antibodies to
VLA-4, a monocyte integrin that binds to VCAM-1,
predictably inhibited binding following TNFa stimula-
Fig. 6. VCAM-1 expression by lipoprotein-stimulated cells. (See Fig. 4.) tion [28.6% (2.8%), P , 0.0001], had only marginal ef-
Growth arrested mesangial cells were exposed to LDL ( ) and MM-
fects on MM-LDL–primed cells [13.6% (4.3%), P 5LDL ( ) for 24 hours and VCAM-1 expression assessed by ELISA.
The absorbance readings (mean 6 sem) obtained from stimulated cells NS], and did not modify adhesion to mesangial cells
are expressed as percentage of control (100%). Results are representa- preincubated with LDL [4.2% (2.7%), P 5 NS]. Anti-
tive of 4 experiments, each conducted in quintuplicate. *P , 0.05 vs.
VLA-5 antibodies also blocked binding of monocytescontrol.
to nonstimulated mesangial cells under basal conditions
(Fig. 7D). A small reduction (of borderline significance)
was also observed with anti-fibronectin antibodies, sug-
tion increased VCAM-1 in a similar time- and concentra- gesting a possible role for this matrix component in medi-
tion-dependent manner. For example, after 24-hour ex- ating monocyte adhesion to resting cells.
posure, VCAM-1 was increased to 179.4% (6.7%, P , In an additional experiment, the effects of a combina-
0.005) of control (100%). In contrast, LDL prestimula- tion of antibodies directed against monocyte integrins
tion did not modify cellular VCAM-1 expression, al- and mesangial cell adhesion molecules were explored.
though a small increase to 116.6% (6.2%, P , 0.05) of
Following prestimulation with MM-LDL, anti-VLA-5,
control was observed at 100 mg/ml MM-LDL in more
and anti-VCAM-1 antibodies inhibited monocyte bind-than one experiment (Fig. 6).
ing to mesangial cells by 45.4% and 12.0%, respectively,
whereas in combination, a 73.3% reduction in adhesionInhibition of monocyte adhesion to mesangial cells
was observed.It was therefore clear that lipoprotein-mediated in-
creases in monocyte adhesion to mesangial cells were Synthesis of fibronectin
unlikely to result from increased expression of ICAM-1
To further explore whether the effects of lipoproteinand VCAM-1. To confirm this, binding experiments were
stimulation on monocyte adhesion might be mediatedrepeated in the presence of blocking antibodies directed
by matrix proteins, the impact of LDL and MM-LDLagainst these cellular adhesion molecules. Because mono-
on mesangial cell fibronectin production was examined.cytes were known to bind fibronectin, additional studies
In keeping with previously published work, both unmod-were undertaken using antibodies to this cellular matrix
ified and mildly oxidized LDL enhanced fibronectin syn-molecule and to monocyte integrins known to bind to
thesis and secretion by cultured mesangial cells [4]. Atit. The optimal concentrations of all antibodies were
concentrations of 100 mg/ml and after a 24-hour incuba-determined from published literature and preliminary
tion, LDL and MM-LDL increased cell-associated fi-dilutional studies. As predicted from the results men-
bronectin to 17.93 6 2.47 ng/mg cell protein (P , 0.05)tioned earlier here, anti-ICAM and anti-VCAM antibod-
and 18.38 6 3.12 (P , 0.05) compared with control cellsies blocked binding to TNFa-primed cells by 40.4%
incubated in RPMI (15.72 6 2.40; Table 1). Incubation(6.5%, P , 0.01) and 26.7% (3.7%, P , 0.01), respec-
with both lipoproteins resulted in a proportionatelytively (Fig. 7A), having smaller inhibitory effects [23.6%
greater rise in secreted fibronectin, thus increasing the(3.2%), P , 0.001, and 15.1% (3.3%), P , 0.05] following
ratio of newly synthesized secreted to cell-associatedMM-LDL prestimulation (Fig. 7B) but no impact on
molecules. Similar results were obtained after 48-hourbinding to cells preincubated with LDL, which had failed
to increase adhesion molecule expression (Fig. 7C). Anti- prestimulation. In contrast, TNFa had virtually no effect
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Fig. 7. Inhibition of monocyte binding to mesangial cells prestimulated with TNFa (A), MM-LDL (B), LDL (C), or unstimulated (D). Human
mesangial cells were rested or prestimulated with TNFa (100 U/ml), MM-LDL (100 mg/ml) or LDL (100 mg/ml) for 24 hours and then incubated
with anti-human ICAM-1 (CD54; 10 mg/ml), anti-human VCAM-1 (CD106; 4 mg/ml) and anti-human fibronectin antibodies (25 mg/ml) for between
2 and 3 hours. A suspension of U-937 monocytes was then added. Alternatively monocytes were incubated with anti-LFA-1 (20 mg/ml), anti-VLA-4
(10 mg/ml) and anti-VLA-5 (5 mg/ml) antibodies for 30 minutes before being adding to rested or prestimulated mesangial cells for one hour. After
washing, adherent monocytes were fixed, stained with crystal violet and solubilized in triton X-100. Absorbance readings were obtained at 595
nm. The results are expressed as mean (sem) absorbance, corrected for the background staining of mesangial cells, as a percentage of control
(100%). These results are representative of 3 to 6 experiments, each conducted in triplicate at optimal antibody concentrations. P vs. control:
*P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001.
on cell-associated fibronectin production but led to a cyte adhesion. Rather than involving recognized adhe-
sion molecules, this interaction appears to be mediated,small increase in secretion of this matrix component.
at least in part, by an increase in the synthesis of fibro-
nectin. Binding was shown to specifically involve the
DISCUSSION monocyte integrin VLA-5, which binds to the RGD se-
These results demonstrate that stimulation of human quence of the fibronectin molecule. In contrast, when
mesangial cells were exposed to TNFa, an increase inmesangial cells with nonoxidized LDL enhances mono-
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Table 1. Production of fibronectin by human mesangial cells fore seems reasonable to assume that the presence of
exposed to low density lipoprotein (LDL), minimally oxidized
LDL within the injured glomerular mesangium promotes(MM)-LDL and tumor necrosis factor alpha (TNFa) for 24 hours
monocyte accumulation. This study suggests that lipo-
Cell layer Conditioned medium protein-induced increases in the synthesis of the matrix
Fibronectin P value Fibronectin P value component fibronectin represent an additional factor
Control 15.72 6 2.40 35.74 6 5.21 that may promote monocyte retention.
LDL 50 lg/ml 17.83 6 2.69 , 0.05 79.04 6 7.70 , 0.001 The adhesion assay used in these experiments was first
LDL 100 lg/ml 17.93 6 2.47 , 0.05 88.0 6 7.70 , 0.001
described by Mene` et al, who demonstrated constitutiveMM-LDL 50 lg/ml 16.79 6 2.28 NS 71.83 6 7.10 , 0.001
MM-LDL 100 lg/ml 18.38 6 3.12 , 0.05 81.73 6 7.62 , 0.001 adhesion of cells of the U-937 myelomonocytic leukemia
TNFa 100 U/ml 16.03 6 2.56 NS 52.13 6 3.56 , 0.05 line to mesangial cells in vitro with associated proliferation
Fibronectin (expressed as ng/mg cell protein) was measured in the cell layer and cytotoxic effects [14, 28]. Up-regulation of binding
extract (cell-associated) and in the conditioned medium by ELISA and corrected
was observed following stimulation with cytokines in-for cell protein as described in the methods. Results are the mean 6 sem of 4
experiments, each performed in quadruplicate. Statistics were performed using cluding TNFa and interleukin-1, and the adhesion assay
a paired Student’s t-test and P values are vs. control.
was validated by repeating the experiments with freshly
isolated human mononuclear cells, which gave nearly
identical results. The increase in binding of U-937 cells
to TNFa-stimulated mesangial cells in this study wasmonocyte adhesion of similar magnitude was observed,
resulting predominantly from enhanced expression of similar to that reported by Mene` et al [14]. Enhanced
monocyte adhesion to mesangial cells was observed fol-the adhesion molecules ICAM-1 and VCAM-1 by the
mesangial cells. Mildly oxidized LDL promoted mono- lowing prestimulation with lipoprotein at concentrations
of less than 100 mg/ml, that is, at physiological plasmacyte-mesangial cell interactions by a combination of both
mechanisms. These data also confirm previous studies LDL levels. Because plasma freely percolates the glo-
merular mesangium, these findings suggest that mesan-demonstrating up-regulation of mesangial cell fibronec-
tin synthesis as a result of lipoprotein stimulation. More gial cells are readily exposed to concentrations of LDL
that might be expected to promote monocyte adhesionimportantly, there was an increase in the production of
cell-associated molecules that was not observed follow- [29]. Both LDL and MM-LDL preparations were dem-
onstrated to be free of endotoxin, making it highly un-ing exposure to TNFa. Accumulation of fibronectin is a
recognized feature of glomerulosclerosis and is likely to likely that the results could be explained by lipopolysac-
charide contamination of the samples.promote entrapment of mononuclear cells within the
glomerular mesangium [19]. To identify the cellular mechanisms of monocyte adhe-
sion to mesangial cells following lipoprotein stimulation,Available evidence from animal studies suggests that
monocytes may mediate scarring in experimentally in- ICAM-1 and VCAM-1 were measured by cell ELISA.
The results showed that even after 48 hours of incubation,duced hyperlipidemia and other animal models of pro-
gressive renal disease [1, 9, 10, 20–22]. For example, in LDL had no effect on the expression of either adhesion
molecule. Although MM-LDL increased cell surfacerats with remnant kidneys, macrophage accumulation
showed a strong correlation with the progression of focal ICAM-1 and VCAM-1, this effect was relatively trivial
when compared with that of TNFa stimulation. Similarsclerosis [9]. Studies in human renal diseases have also
demonstrated monocyte accumulation in most forms of effects of lipoproteins on adhesion molecule expression
have been reported in vascular smooth muscle cells, hu-glomerulonephritis, including those associated with pro-
gressive fibrosis [23, 24]. man aortic endothelial cells, and human umbilical vein
endothelial cells [30, 31]. However, despite enhancingMonocyte recruitment to the mesangium, or any site
of injury, involves a series of co-ordinated events that monocyte adhesion, neither LDL nor modified lipopro-
tein were shown to induce the expression of eitherallow specific targeting of immune cells to appropriate
target organs and tissues [25]. Key events in this process ICAM-1 or VCAM-1. Consistent with this study, the
cytokine TNFa consistently increased the expression ofinclude the local production of chemotactic substances
and the expression of adhesion molecules on relevant both adhesion molecules in glomerular cells [14, 32, 33].
The importance of adhesion molecule induction inareas of vascular endothelium. As has been demon-
strated in atherosclerosis, the presence of lipoproteins mediating the observed effects of TNFa on monocyte
adhesion to mesangial cells was illustrated by studiesin the interstitium may promote these processes [26].
Although it has been difficult to study glomerular endo- using blocking antibodies. Both anti-ICAM-1 or anti-
VCAM-1 inhibited TNFa-mediated increases in mono-thelial cells, up-regulation of adhesion molecule expres-
sion has been shown in vascular endothelium adjacent to cyte adhesion, although neither completely prevented
this process, suggesting that other adhesion moleculeslipid deposits [27]. Furthermore, exposure of mesangial
cells to LDL stimulates production of the potent chemo- (possibly ICAM-2 and ICAM-3) were involved. Like
ICAM-1, these cell adhesion molecules are counter re-kine, monocyte chemoattractant protein-1 [4]. It there-
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ceptors for the monocyte integrin LFA-1, although in cytes within the mesangium through hyaluronan–CD44
interactions [43].this study an anti-LFA-1 antibody did not completely
In summary, enhanced monocyte adhesion to LDL-block the cytokine-mediated increase in monocyte
primed human mesangial cells does not involve ICAM-1binding [13]. The induction of monocyte adhesion by
or VCAM-1, but is mediated, at least in part, by anMM-LDL was partly inhibited by anti-ICAM-1, anti-
interaction between cell-associated fibronectin and theVCAM-1, and anti-LFA-1 antibodies, reflecting the
monocyte integrin VLA-5. Mildly oxidized LDL inducedmodest rise in expression of ICAM-1 and VCAM-1 mol-
a small increase in ICAM-1 and VCAM-1, which ap-ecules that had been demonstrated following stimulation
peared to be functionally important in the binding pro-with mildly oxidized lipoprotein. In contrast, monocyte
cess. In contrast, TNFa enhanced monocyte binding toadhesion to LDL-stimulated mesangial cells was not in-
mesangial cells, largely by up-regulation of mesangial cellhibited by the presence of these antibodies, suggesting
ICAM-1 and VCAM-1 expression. These results suggestthat up-regulation of cell adhesion molecules was not
that monocyte retention in the glomerular mesangium,important.
a feature of early glomerular injury in hyperlipidemicFibronectin is a major glomerular matrix component
animal models, may be mediated by increased mesangialand is synthesized by mesangial cells, being present on
cell fibronectin production. Inhibition of this interactionthe cell surface, in the extracellular matrix of the mesan-
represents a potential therapeutic intervention thatgium and in a soluble form in plasma [5]. Deposition of
might prove protective.a fibronectin-rich organized matrix is likely to depend
on the ability of these cells to interact with newly secreted
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APPENDIXto matrix components and include VLA-4 and VLA-5
[12, 36]. Potential interactions between monocytes and Abbreviations used in this article are: ICAM-1, intercellular adhe-
sion molecule-1; LDL, low-density lipoprotein; LFA-1, leukocyte func-fibronectin therefore include binding of VLA-5 to the
tional associated molecule-1; MM-LDL, minimally modified-LDL;RGD sequence [37, 38] and of VLA-4 to the CS-1 and
PBS, phosphate-buffered saline; TNFa, tumor necrosis factor a;
CS-5 regions of the IIICS domain of the molecule [39, VCAM-1, vascular cell adhesion molecule-1; VLA-4, very late
antigen-4.40]. Interactions between cell surface receptors and fi-
bronectin have been shown to mediate attachment to
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